EUVIMEDEUVIMED entdecken
Open Access

Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML

Emily C Wheeler iD, Benjamin J E Martin iD, William C Doyle iD, Sofia Neaher, Caroline A Conway iD, Caroline N Pitton iD, Rebecca A Gorelov, Melanie Donahue, Johann C Jann iD, Omar Abdel-Wahab iD, Justin Taylor iD, Michael Seiler und 6 weitere

Science Translational Medicine · 03.01.2024 · 16 (728)

DOI: 10.1126/scitranslmed.ade2774 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 03.01.2024. Verfasst von Emily C Wheeler und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Splicing modulation is a promising treatment strategy pursued to date only in splicing factor-mutant cancers; however, its therapeutic potential is poorly understood outside of this context. Like splicing factors, genes encoding components of the cohesin complex are frequently mutated in cancer, including myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (AML), where they are associated with poor outcomes. Here, we showed that cohesin mutations are biomarkers of sensitivity to drugs targeting the splicing factor 3B subunit 1 (SF3B1) H3B-8800 and E-7107. We identified drug-induced alterations in splicing, and corresponding reduced gene expression, of a number of DNA repair genes, including BRCA1 and BRCA2 , as the mechanism underlying this sensitivity in cell line models, primary patient samples and patient-derived xenograft (PDX) models of AML. We found that DNA damage repair genes are particularly sensitive to exon skipping induced by SF3B1 modulators due to their long length and large number of exons per transcript. Furthermore, we demonstrated that treatment of cohesin-mutant cells with SF3B1 modulators not only resulted in impaired DNA damage response and accumulation of DNA damage, but it sensitized cells to subsequent killing by poly(ADP-ribose) polymerase (PARP) inhibitors and chemotherapy and led to improved overall survival of PDX models of cohesin-mutant AML in vivo. Our findings expand the potential therapeutic benefits of SF3B1 splicing modulators to include cohesin-mutant MDS and AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesLeukemia, Myeloid, AcuteHumansCohesinsRNA SplicingRNA Splicing FactorsMutationTranscription FactorsDNA RepairPhosphoproteinsDNA Damage

Substanzen

CohesinsRNA Splicing FactorsTranscription FactorsPhosphoproteins

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Broad Institute of MIT and Harvard University, Cambridge, MA 02142, USA.
  • Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.
  • Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
  • Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, Miami, FL 33136, USA.
  • H3 Biomedicine Inc., 300 Technology Square, Cambridge, MA 02139, USA.

ORCID-Profile: Emily C Wheeler, Benjamin J E Martin, William C Doyle, Caroline A Conway, Caroline N Pitton, Johann C Jann, Omar Abdel-Wahab, Justin Taylor, Yana Pikman, Roger Belizaire, Karen Adelman, Zuzana Tothova

Förderung

  • NCI NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Wheeler, E. C., Martin, B. J. E., Doyle, W. C., Neaher, S., Conway, C. A., Pitton, C. N., Gorelov, R. A., Donahue, M., Jann, J. C., Abdel-Wahab, O., Taylor, J., Seiler, M., Buonamici, S., Pikman, Y., Garcia, J. S., Belizaire, R., Adelman, K., & Tothova, Z. (2024). Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML. Science Translational Medicine, 16(728). https://doi.org/10.1126/scitranslmed.ade2774

Vancouver

Wheeler EC, Martin BJE, Doyle WC, Neaher S, Conway CA, Pitton CN, et al. Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML. Science Translational Medicine. 2024;16(728). doi:10.1126/scitranslmed.ade2774

BibTeX
@article{Wheeler2024,
  author = {Wheeler, Emily C and Martin, Benjamin J E and Doyle, William C and Neaher, Sofia and Conway, Caroline A and Pitton, Caroline N and Gorelov, Rebecca A and Donahue, Melanie and Jann, Johann C and Abdel-Wahab, Omar and Taylor, Justin and Seiler, Michael and Buonamici, Silvia and Pikman, Yana and Garcia, Jacqueline S and Belizaire, Roger and Adelman, Karen and Tothova, Zuzana},
  title = {Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML},
  journal = {Science Translational Medicine},
  year = {2024},
  volume = {16},
  number = {728},
  doi = {10.1126/scitranslmed.ade2774}
}
Kostenlos starten →